DCTH achieved a remarkable turnaround from -$26.4M net loss to $2.7M profit while more than doubling revenue to $85.2M, driven by successful HEPZATO commercialization.
This represents a transformative financial performance with the company achieving profitability for the first time, indicating successful market adoption of their HEPZATO treatment for uveal melanoma. The strong revenue growth coupled with positive operating cash flow of $22.5M (vs. -$18.7M outflow previously) demonstrates sustainable business momentum and validates their commercial strategy.
DCTH delivered exceptional across-the-board financial improvement with revenue more than doubling to $85.2M and gross profit surging 137% to $73.4M, while simultaneously achieving profitability with $2.7M net income versus a $26.4M loss previously. The company generated positive operating cash flow of $22.5M compared to an $18.7M outflow, and strengthened its balance sheet with current assets growing 62% to $119.5M and stockholders' equity increasing to $111.2M. Despite higher R&D spending reflecting continued investment in growth, the overall financial picture signals a successful transition from development-stage losses to sustainable profitability and strong cash generation.
Operating cash flow surged 220.5% — exceptional cash generation, highest quality earnings signal.
Capital expenditure jumped 176.7% — major investment cycle underway; assess returns on deployment.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Strong top-line growth of 129.1% — accelerating demand or successful expansion into new markets.
R&D investment increased 110.8% — signals commitment to future product development, though near-term margin impact.
Net income grew 110.2% — bottom-line growth signals improving overall business health.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Current liabilities surged 78.2% — significant near-term obligations; verify ability to meet short-term debt.
Current assets grew 62.1% — improving short-term liquidity or inventory/receivables build.
Equity base grew 61.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →